65,437 trials
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Glycosylated Hemoglobin (HbA1c) Value at 12 Week Endpoint — 7.91; 7.96 percent of glycosylated hemoglobin — p=0.497
Type 2 Diabetes
Primary: Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg) — 53.4; 19.8 percentage of participants — p=<0.001
Psoriasis
Primary: Proportion of Subjects With a Physician's Global Assessment (PGA) Rating of Clear (0), Almost Clear (1), or Mild (2) — 34.8 percentage
ADHD
Primary: Onset of Effect of Vyvanse — 0.70; 1.14; 0.45; 1.42 scores on a scale — p=<0.0001
Prostate Cancer
Primary: Time to Meet Insufficient Testosterone Response — 14; 77; 98; 28 days — p=<0.001
Healthy
Primary: Maraviroc Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-time Profile Over the Dosing Interval (AUCτ) — 2551.9; 2971.6 ng.hr/mL
Type 2 Diabetes Mellitus
Primary: The Percentage of Patients Achieving HbA1c <=7% at Week 24 With no Gain in Body Weight From Baseline and no Incidence of Severe Hypoglycemia — 30.4; 10.7 Percent…
Hepatitis B · Hepatitis A
Primary: Anti-hepatitis A (HAV) Antibody Concentrations — 1122.2; 1377.8; 998.6; 1347.1 mIU/mL
Chronic Kidney Disease · Endothelial Dysfunction · Inflammation
Primary: Anti-Inflammatory Effects of Paricalcitol — .8; .5; 1.5 micrograms
Pain · Osteoarthritis, Knee
Primary: Adverse Events: 12-months Safety Population — 14; 9; 1; 9 participants
Influenza
Primary: Number of Participants Reporting Solicited Injection Site and Solicited Systemic Reactions After Fluzone® Vaccination — 40; 10; 4; 6 Participants
Acute Cardiogenic Pulmonary Edema
Primary: Number of Patients Who Were Intubated — 5; 4; 10 participants
Insomnia
Primary: Mean Change From Baseline in Subject-Reported Total Sleep Time (TST) Averaged Over the 12 Week Double Blind Study Period. — 33.18; 63.24 minutes — p=<0.0001
Healthy
Primary: AUC(0-t) — 2064; 4332; 6568 ng.h/mL
Kidney Failure · Graft vs Host Disease
Primary: Number of Patients With Biopsy Confirmed Acute Rejection at 12 Months Follow up. — 3; 3; 21; 20 participants — p=1.0